The Anti-Aging Compound Spermidine Has a Dark Side in Old T Cells
Spermidine is widely promoted as an anti-aging polyamine, but a new mouse-derived cell study found it can sabotage a specific group of old immune cells. In senescence-like CD49d- CD8+ T cells, it cut mitochondrial respiration, depleted antioxidant reserves, and fragmented mitochondria, while neighboring CD49d+ cells were untouched. Cells from young mice responded differently, which makes age a key variable. This is preclinical work, not evidence of harm in humans, but it challenges the idea that spermidine helps every aging cell. Here's what the paper found and what it does and doesn't mean for you.
NR Lowered Muscle Epigenetic Age. HIIT Pushed the Other Way
NR and HIIT are both billed as ways to keep muscle young, but a new Aging Cell paper found they can pull epigenetic clocks in opposite directions. Five months of nicotinamide riboside was associated with reduced muscle epigenetic age acceleration, especially on the PCHannum, MEAT, and DunedinPACE clocks. HIIT moved some clocks the other way, raising the pace of aging on DunedinPACE. The link between the two may be mitochondria, since changes in muscle mitochondrial content correlated with changes in MEAT-based age acceleration. Here is what the study actually shows, what it doesn't, and how to read it without overreacting.
Your CoQ10 Reaches Your Blood, But Not Your Mitochondria
A new human trial put a hugely popular longevity supplement to the test with muscle biopsies, and the results are awkward for the marketing. In 40 healthy adults averaging 74 years, 400 mg/day of CoQ10 for 12 weeks raised blood levels but left muscle and mitochondrial CoQ10 unchanged. Mitochondrial function, VO2max, glucose control and body composition did not move either. The study is small, short and limited to robust older adults, and the senior author consults for Pharma Nord. Here is what it shows, what it cannot say, and who might still want to ask a doctor about CoQ10.
NMN Calms Muscle Inflammation After Training—But at What Cost?
NMN is sold as a cellular-energy booster, but a new muscle-biopsy study found a surprising tradeoff. After a damaging blood flow restriction workout, 1,200 mg/day of NMN suppressed inflammatory signals like TNF-α and IL-10. It also delayed a repair-related marker and erased the 171% mitochondrial increase seen with placebo. The study is tiny (11 untrained young men), so it can't settle anything. It does challenge the assumption that less post-workout inflammation is always better.
Urolithin A Didn't Fix Arteries in 4 Weeks, but the Brain Responded
A double-blind trial of 50 adults aged 40-64 with obesity found that 1,000 mg of urolithin A daily for four weeks did not improve flow-mediated dilation, the study's primary endpoint. Peripheral microvascular measures were also unchanged. Yet task-evoked cerebrovascular hemodynamic responses were significantly greater with urolithin A than with placebo, even though task performance did not budge. Because the brain result is a secondary outcome from a short, small trial, it is a lead rather than a conclusion. Here is what the data show, what they don't, and what it means for anyone considering the supplement.
PQQ Boosted Memory in 12 Weeks, in Both Young and Older Adults
A double-blind, placebo-controlled trial found that 20 mg/day of PQQ disodium salt improved memory scores in adults aged 20-65 after 12 weeks. The timing differed by age: younger adults gained on cognitive flexibility and speed by week 8, while adults aged 41-65 improved on verbal and complex memory at week 12. The catch is that the authors work for Mitsubishi Gas Chemical, which makes a PQQ ingredient, and the abstract omits the sample size. Here is what the study showed, what it didn't, and how to read it before you buy a bottle.
One Shot Made Old Mouse Muscle Mitochondria Act Young in 1 Hour
A single injection of SS-31 (elamipretide) restored muscle mitochondrial energy production in very old mice to young levels within one hour. That result comes from a 2013 mouse study, not from human trials. The peptide had no observable effect on young muscle, and eight days of treatment improved endurance in the old animals. In humans, elamipretide won FDA accelerated approval for Barth syndrome but missed its primary endpoints in the MMPOWER-3 mitochondrial myopathy trial. Here is what the study showed, where it falls short, and why grey-market versions are a bad idea.